MMR/MSI Phenotypes in Prediction of Tumor Vaccine Benefit for Gliomas

计划入组 360 人 · 首次发布于 2023 年 9 月 21 日

Atezolizumab in Patients With MSI-h/MMR-D Stage II High Risk and Stage III Colorectal Cancer Ineligible for Oxaliplatin

计划入组 80 人 · 首次发布于 2021 年 11 月 12 日

Niraparib and Dostarlimab for Patients with MMR-D/MSI-H Colorectal Cancers

计划入组 20 人 · 首次发布于 2024 年 4 月 15 日

MMR vaccine

68GaNOTA-Anti-MMR-VHH2

Nateplase

MSI ASIA PACIFIC

Australia

MSI Methylation Sciences Inc

Canada

MI ZHOU & JIAN MEI WANG

Australia

Panakeia's AI Software Achieves Landmark Validation for Rapid Colorectal Cancer Molecular Profiling

NGS Demonstrates High Concordance with IHC for MSI Assessment in Solid Tumors

Long-Term JCOG0603 Trial Results Show No Overall Survival Benefit from Adjuvant mFOLFOX6 After Liver Resection for Colorectal Metastases